JUMPCAN: The cooperative product Marcilosavir tablets have obtained the drug registration certificate
I'm LongbridgeAI, I can summarize articles.JUMPCAN announced that its wholly-owned subsidiary has obtained the drug registration certificate from the National Medical Products Administration for the drug Marcilosavir tablets, developed in collaboration with Nanjing Zhengxiang Pharmaceutical Co., Ltd. This drug is a Class 1 new drug with broad-spectrum anti-influenza virus properties, suitable for healthy adults with uncomplicated type A and B influenza
According to the Zhitong Finance APP, JUMPCAN (600566.SH) announced that its wholly-owned subsidiary JUMPCAN Pharmaceutical Group Co., Ltd. (referred to as "JUMPCAN Limited") has received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for the development of Marcilosavir tablets in cooperation with Nanjing Zhengxiang Pharmaceutical Co., Ltd. (referred to as "Zhengxiang Pharmaceutical").
Marcilosavir tablets are a Class 1 new drug declared by Zhengxiang Pharmaceutical and are a new generation of polymerase acidic protein (PA) nucleic acid endonuclease inhibitors, characterized by broad-spectrum anti-influenza virus properties. The approved indication is for the treatment of previously healthy adults with uncomplicated type A and B influenza, excluding patients at high risk of influenza-related complications